Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia

The availability of kinase and other small‐molecule inhibitors to treat hematologic malignancies is increasing. Accordingly, novel regimens that employ these therapeutics are rapidly evolving. Herein we report the safe and effective administration of two targeted kinase inhibitors in a patient with...

Descripción completa

Detalles Bibliográficos
Autores principales: Shea, Lauren K., Mikhail, Fady M., Forero‐Torres, Andres, Davis, Randall S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458012/
https://www.ncbi.nlm.nih.gov/pubmed/28588835
http://dx.doi.org/10.1002/ccr3.974
_version_ 1783241663066406912
author Shea, Lauren K.
Mikhail, Fady M.
Forero‐Torres, Andres
Davis, Randall S.
author_facet Shea, Lauren K.
Mikhail, Fady M.
Forero‐Torres, Andres
Davis, Randall S.
author_sort Shea, Lauren K.
collection PubMed
description The availability of kinase and other small‐molecule inhibitors to treat hematologic malignancies is increasing. Accordingly, novel regimens that employ these therapeutics are rapidly evolving. Herein we report the safe and effective administration of two targeted kinase inhibitors in a patient with concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia.
format Online
Article
Text
id pubmed-5458012
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54580122017-06-06 Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia Shea, Lauren K. Mikhail, Fady M. Forero‐Torres, Andres Davis, Randall S. Clin Case Rep Case Reports The availability of kinase and other small‐molecule inhibitors to treat hematologic malignancies is increasing. Accordingly, novel regimens that employ these therapeutics are rapidly evolving. Herein we report the safe and effective administration of two targeted kinase inhibitors in a patient with concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia. John Wiley and Sons Inc. 2017-04-24 /pmc/articles/PMC5458012/ /pubmed/28588835 http://dx.doi.org/10.1002/ccr3.974 Text en © 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Shea, Lauren K.
Mikhail, Fady M.
Forero‐Torres, Andres
Davis, Randall S.
Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
title Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
title_full Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
title_fullStr Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
title_full_unstemmed Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
title_short Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
title_sort concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458012/
https://www.ncbi.nlm.nih.gov/pubmed/28588835
http://dx.doi.org/10.1002/ccr3.974
work_keys_str_mv AT shealaurenk concomitantimatinibandibrutinibinapatientwithchronicmyelogenousleukemiaandchroniclymphocyticleukemia
AT mikhailfadym concomitantimatinibandibrutinibinapatientwithchronicmyelogenousleukemiaandchroniclymphocyticleukemia
AT forerotorresandres concomitantimatinibandibrutinibinapatientwithchronicmyelogenousleukemiaandchroniclymphocyticleukemia
AT davisrandalls concomitantimatinibandibrutinibinapatientwithchronicmyelogenousleukemiaandchroniclymphocyticleukemia

Ejemplares similares